Publikationen
CUTIMED® EPIONA CLINICAL STUDY
FAST FACTS ON A NEW 3D MATRIX ™ TECHNOLOGY THAT FAST-TRACKED HEALING FOR CHRONIC WOUNDS
Clinical study evaluated the effectiveness of Cutimed® Epiona when administered with standard of care, based on wound etiology, of 31 patients
Study performed up to 4 weeks at wound care centers in the U.S.
Primary endpoint was reduction in wound area
Wounds were mainly diabetic foot ulcers (DFUs; 42%) and venous leg ulcers (VLUs; 32%); the remainder were other types of chronic wounds
Biological wound matrices with native dermis-like collagen efficiently modulate protease activity
When the delicate balance between catabolic and anabolic processes is disturbed for any reason, the healing process can stall, resulting in chronic wounds. In chronic wound pathophysiology, proteolytic imbalance is implicated due to elevated protease levels
mediating tissue damage. Hence, it is important to design appropriate wound treatments able to control and modulate protease activity directly at the host/biomaterial interface. Here, we investigate collagen-based wound dressings with the focus on their potential to adsorb and inactivate tissue proteases.
A novel native collagen dressing with advantageous properties to promote physiological
wound healing
Objective: Chronic hard-to-heal wounds generate high costs and resource use in western health systems and are the focus of intense efforts to improve healing outcomes. Here, we introduce a novel native collagen (90 %):alginate (10 %) wound dressing and compare it with the established oxidised dressings.